Guided Therapeutics (GTHP) Net Margin (2010 - 2025)
Guided Therapeutics (GTHP) reported Net Margin of 202.71% for Q4 2025, up 6979729.0% on a YoY basis from N/an in Q4 2024, and up 84.51% sequentially from 1308.33% in Q3 2025.
Guided Therapeutics (GTHP) Net Margin (2010 - 2025) Analysis & Trends
Guided Therapeutics (GTHP) has 16 years of Net Margin data on file, last reported at 202.71% in Q4 2025.
- For the quarter ending Q4 2025, Net Margin rose 6979729.0% year-over-year to 202.71%; the trailing twelve-month figure through Dec 2025 stood at 430.25% (up 3658404.0% YoY), and the FY2025 full-year result was 430.25%, up 3658404.0% from the prior year.
- Net Margin rose to 202.71% in Q4 2025, from 1308.33% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 202.71% in Q4 2025 to a low of 70000.0% in Q4 2024.
- A 5-year average of 16039.17% and a median of 4025.0% in 2023 frame the typical range for Net Margin.
- Across the five-year window, Net Margin slumped 6853438 bps in 2024 and soared 6979729 bps in 2025, its largest moves.
- Tracing GTHP's Net Margin over 5 years: stood at 848.33% in 2021, then sank by 4041 bps to 35133.33% in 2022, then jumped by 96 bps to 1465.62% in 2023, then slumped by 4676 bps to 70000.0% in 2024, then jumped by 100 bps to 202.71% in 2025.
- Business Quant data shows GTHP's Net Margin at 202.71% in Q4 2025, 1308.33% in Q3 2025, and 731.62% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.52 Bn | 175.22 Bn | 6.27 Bn | 9.65% |
| 2 | Stryker | 128.96 Bn | 126.09 Bn | 3.81 Bn | 12.38% |
| 3 | Medtronic | 107.99 Bn | 98.77 Bn | 6.41 Bn | 12.84% |
| 4 | Boston Scientific | 67.76 Bn | 66.31 Bn | 3.61 Bn | 25.77% |
| 5 | Edwards Lifesciences | 48.09 Bn | 44.41 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.30 Bn | 27.18 Bn | 750.30 Mn | 16.74% |
| 7 | GE HealthCare Technologies | 27.89 Bn | 25.61 Bn | 1.98 Bn | 8.01% |
| 8 | Smith & Nephew | 27.02 Bn | 26.45 Bn | - | - |
| 9 | Koninklijke Philips | 23.98 Bn | 20.86 Bn | 2.07 Bn | 3.87% |
| 10 | Guided Therapeutics | 20.78 Mn | 20.72 Mn | 458,000.00 | -202.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -202.71% |
| Sep 30, 2025 | -1,308.33% |
| Jun 30, 2025 | -731.62% |
| Dec 31, 2024 | -70,000.00% |
| Mar 31, 2024 | -7,350.00% |
| Dec 31, 2023 | -1,465.63% |
| Jun 30, 2023 | -3,645.45% |
| Mar 31, 2023 | -4,404.55% |
| Sep 30, 2022 | -35,133.33% |
| Jun 30, 2022 | -20,140.00% |
| Mar 31, 2022 | -21,100.00% |
| Dec 31, 2021 | -848.33% |
| Sep 30, 2021 | -268.42% |
| Jun 30, 2021 | -57,950.00% |
| Dec 31, 2020 | 8,476.00% |
| Sep 30, 2020 | 1,985.71% |
| Dec 31, 2019 | 6,768.75% |
| Sep 30, 2019 | -12,600.00% |
| Jun 30, 2019 | -265,400.00% |
| Mar 31, 2019 | -1,244.44% |